PLAKOUS THERAPEUTICS, INC.
Pfafftown, NC · Founded 2016 · CIK 0001709440 · Biotech · Private
Protego-PD, an acellular placental preparation containing cytokines and growth factors for oral administration to prevent necrotizing enterocolitis in preterm infants
plakoustherapeutics.com →- Grants
- $5.4M
- 6 awards
- Sector median: 1
- Raised
- $185K
- 2 Form D · Jan 2020
- 81 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 15
- 3 granted · 12 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $10,000 | |
| Private capital raised | Form D · SEC | $175,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a human placental extract for the prevention of necrotizing enterocolitis in premature babies | $224,998 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a human placental extract for the prevention of necrotizing enterocolitis in premature babies | $1,525,638 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a human placental extract for the prevention of necrotizing enterocolitis in premature babies | $755,655 | |
| Federal grant | Department of Health and Human Services · Phase II · IND Enabling Studies and Manufacturing Scale Up of Human Placental Extract to Prevent Surgical Necrotizing Enterocolitis | $1,121,897 | |
| Federal grant | Department of Health and Human Services · Phase II · IND Enabling Studies and Manufacturing Scale Up of Human Placental Extract to Prevent Surgical Necrotizing Enterocolitis | $976,322 | |
| Federal grant | Department of Health and Human Services · Phase II · IND Enabling Studies and Manufacturing Scale Up of Human Placental Extract to Prevent Surgical Necrotizing Enterocolitis | $826,522 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1201 | Obatala Sciences, Inc. | — | $200K |
| 1202 | Oncorus, Inc. | — | $47M |
| 1203 | Qlaris Bio, Inc. | — | $42M |
| 1204 | PLAKOUS THERAPEUTICS, INC. | — | $185K |
| 1205 | ADIAL PHARMACEUTICALS, INC. | — | $38M |
| 1206 | FORWARD DEFENSE, LLC | — | — |
| 1207 | Gigagen, Inc. | — | $36M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Robert BoyceExecutive Officer
- Allison BrownDirector
- Peter JohnsonDirector
- Seth TomblynDirector · Executive Officer
- Scott WashburnDirector · Executive Officer
Patents
- Acellular Placental Preparationsapplication
- Acellular Placental Preparationsgranted
- Acellular Placental Therapiesapplication
- Acellular Placental Therapiesapplication
- Placental Tissue Compositionsapplication
- Methods of Preparing and Using Placental Tissue Compositionsgranted
- Acellular Placental Therapies For Necrotizing Enterocolitisapplication
- Placental Tissue Compositionsgranted
- Acellular Placental Preparationsapplication
- Acellular Placental Therapiesapplication
- Acellular Placental Therapiesapplication
- Acellular Placental Therapiesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.